ERBB2 and breast carcinoma: A neo-adjuvant chemotherapy-treated cohort of 312 breast cancer patients was formed, consisting of Luminal A (n = 108), Luminal B (n = 122), HER2-positive (n = 41), and Triple negative/basal (n = 43) patients with a follow-up of at least 3 years (Table 1).